Results for tag: "Omecamtiv"

Omecamtiv is a class of cardiovascular drugs used to treat heart failure. It works by increasing the contractility of the heart muscle, allowing it to pump more blood with each beat. This helps to reduce the symptoms of heart failure, such as shortness of breath and fatigue. Omecamtiv is the first in a new class of drugs known as myosin activators, which are designed to improve the efficiency of the heart muscle. The Omecamtiv market is a rapidly growing segment of the cardiovascular drug market. It is expected to be a major driver of growth in the coming years, as more patients are diagnosed with heart failure and the need for effective treatments increases. Omecamtiv is currently approved in the US and Europe, and is being studied in other countries. Some of the companies in the Omecamtiv market include Amgen, AstraZeneca, and Cytokinetics. These companies are developing and marketing Omecamtiv for the treatment of heart failure. Other companies, such as Novartis and Pfizer, are also researching and developing Omecamtiv-based treatments. Show Less Read more